{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:51:12Z","timestamp":1795179072758,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72984-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:25:10Z","timestamp":1778149510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2523","authenticated-orcid":false,"given":"Glenn J.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7089-2643","authenticated-orcid":false,"given":"Tulika R.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni M.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Tishler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Pashtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4677-461X","authenticated-orcid":false,"given":"Alexander","family":"Droznin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gunasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Minken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Mukundan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-6943","authenticated-orcid":false,"given":"Kartik","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack M.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham H.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daribelle","family":"Massiel Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosh K.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Annino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Goguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Guenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Bakhtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie Y.","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Uppaluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-0401","authenticated-orcid":false,"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"72984_CR1","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","volume":"30","author":"GJ Hanna","year":"2024","unstructured":"Hanna, G. J. et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin. Cancer Res. 30, 3329\u20133336 (2024).","journal-title":"Clin. Cancer Res."},{"key":"72984_CR2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"72984_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511885 (2025).","journal-title":"N. Engl. J. Med"},{"key":"72984_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison, M. L. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393, 40\u201350 (2019).","journal-title":"Lancet"},{"key":"72984_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna, H. et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393, 51\u201360 (2019).","journal-title":"Lancet"},{"key":"72984_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamaoto.2022.3282","volume":"148","author":"EM Rettig","year":"2022","unstructured":"Rettig, E. M. et al. Association of pretreatment circulating tumor tissue-modified viral HPV DNA With clinicopathologic Factors in HPV-positive oropharyngeal cancer. JAMA Otolaryngol. Head. Neck Surg. 148, 1120\u20131130 (2022).","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"72984_CR7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.34109","volume":"128","author":"CJ O\u2019Boyle","year":"2022","unstructured":"O\u2019Boyle, C. J. et al. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. Cancer 128, 2193\u20132204 (2022).","journal-title":"Cancer"},{"key":"72984_CR8","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","volume":"25","author":"BS Chera","year":"2019","unstructured":"Chera, B. S. et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin. Cancer Res. 25, 4682\u20134690 (2019).","journal-title":"Clin. Cancer Res."},{"key":"72984_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","volume":"38","author":"BS Chera","year":"2020","unstructured":"Chera, B. S. et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-Associated Oropharyngeal Cancer. J. Clin. Oncol. 38, 1050\u20131058 (2020).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","volume":"40","author":"RL Ferris","year":"2022","unstructured":"Ferris, R. L. et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311). J. Clin. Oncol. 40, 138\u2013149 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.19.01007","volume":"37","author":"BS Chera","year":"2019","unstructured":"Chera, B. S. et al. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 37, 2661\u20132669 (2019).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","volume":"35","author":"S Marur","year":"2017","unstructured":"Marur, S. et al. E1308: phase II Trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients With HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. J. Clin. Oncol. 35, 490\u2013497 (2017).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","volume":"20","author":"AC Nichols","year":"2019","unstructured":"Nichols, A. C. et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 20, 1349\u20131359 (2019).","journal-title":"Lancet Oncol."},{"key":"72984_CR14","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","volume":"39","author":"SS Yom","year":"2021","unstructured":"Yom, S. S. et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J. Clin. Oncol. 39, 956\u2013965 (2021).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","volume":"42","author":"NY Lee","year":"2024","unstructured":"Lee, N. Y. et al. Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma. J. Clin. Oncol. 42, 940\u2013950 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548\u2013554 (2014).","journal-title":"Nat. Med."},{"key":"72984_CR17","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-24-2575","volume":"31","author":"VK Morris","year":"2025","unstructured":"Morris, V. K. et al. Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer. Clin. Cancer Res. 31, 2399\u20132405 (2025).","journal-title":"Clin. Cancer Res."},{"key":"72984_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.23.00954","volume":"42","author":"K Han","year":"2024","unstructured":"Han, K. et al. Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer. J. Clin. Oncol. 42, 431\u2013440 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1116","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin. Transl. Med. 12, e1116 (2022).","journal-title":"Clin. Transl. Med."},{"key":"72984_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.chest.2021.04.016","volume":"160","author":"MR Roosan","year":"2021","unstructured":"Roosan, M. R. et al. Usefulness of circulating tumor DNA in identifying somatic mutations and tracking tumor evolution in patients with non-small cell lung cancer. Chest 160, 1095\u20131107 (2021).","journal-title":"Chest"},{"key":"72984_CR21","first-page":"164","volume":"73","author":"JJ Kang","year":"2023","unstructured":"Kang, J. J. et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J. Clin. 73, 164\u2013197 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"72984_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdy522","volume":"30","author":"TY Seiwert","year":"2019","unstructured":"Seiwert, T. Y. et al. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann. Oncol. 30, 297\u2013302 (2019).","journal-title":"Ann. Oncol."},{"key":"72984_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","volume":"18","author":"AM Chen","year":"2017","unstructured":"Chen, A. M. et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 18, 803\u2013811 (2017).","journal-title":"Lancet Oncol."},{"key":"72984_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","volume":"95","author":"K Misiukiewicz","year":"2019","unstructured":"Misiukiewicz, K. et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial. Oral. Oncol. 95, 170\u2013177 (2019).","journal-title":"Oral. Oncol."},{"key":"72984_CR25","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1200\/JCO.2021.39.15_suppl.6058","volume":"39","author":"MR Posner","year":"2021","unstructured":"Posner, M. R. et al. Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC). J. Clin. Oncol. 39, 6058\u20136058 (2021).","journal-title":"J. Clin. Oncol."},{"key":"72984_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","volume":"10","author":"AJ Rosenberg","year":"2024","unstructured":"Rosenberg, A. J. et al. Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial. JAMA Oncol. 10, 923\u2013931 (2024).","journal-title":"JAMA Oncol."},{"key":"72984_CR27","doi-asserted-by":"crossref","unstructured":"Yom S. S. et al. Interim futility results of NRG-HN005, a randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients. Paper Presented During the Plenary Session at the Annual Meeting of the American Society For Radiation Oncology. (Washington, DC, 2024).","DOI":"10.1016\/j.ijrobp.2024.08.014"},{"key":"72984_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djaa184","volume":"113","author":"N Riaz","year":"2021","unstructured":"Riaz, N. et al. Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. J. Natl. Cancer Inst. 113, 742\u2013751 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"72984_CR29","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2967\/jnumed.124.267775","volume":"65","author":"R Wray","year":"2024","unstructured":"Wray, R. et al. Development of 18F-fluoromisonidazole hypoxia PET\/CT diagnostic interpretation criteria and validation of interreader reliability, reproducibility, and performance. J. Nucl. Med. 65, 1526\u20131532 (2024).","journal-title":"J. Nucl. Med"},{"key":"72984_CR30","doi-asserted-by":"publisher","unstructured":"Kim J. K. et al. A phase 2 exploratory trial evaluating computed tomography-based midtreatment nodal response to select for de-escalated chemoradiation therapy in the definitive management of p16+ oropharyngeal cancer. Int. J. Radiat. Oncol Biol. Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.054. (2025).","DOI":"10.1016\/j.ijrobp.2025.09.054"},{"key":"72984_CR31","doi-asserted-by":"publisher","unstructured":"Rettig E. M. et al. Prospective trial of biomarker-guided surveillance for hpv-positive oropharynx cancer using plasma tumor tissue modified viral HPV DNA. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3053 (2024).","DOI":"10.1158\/1078-0432.CCR-24-3053"},{"key":"72984_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/fvl.10.73","volume":"6","author":"VM Williams","year":"2011","unstructured":"Williams, V. M., Filippova, M., Soto, U. & Duerksen-Hughes, P. J. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol. 6, 45\u201357 (2011).","journal-title":"Future Virol."},{"key":"72984_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2021.102915","volume":"42","author":"SY Chen","year":"2021","unstructured":"Chen, S. Y. et al. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Am. J. Otolaryngol. 42, 102915 (2021).","journal-title":"Am. J. Otolaryngol."},{"key":"72984_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"72984_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24\u201335 (2010).","journal-title":"N. Engl. J. Med."},{"key":"72984_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/biostatistics\/kxx030","volume":"19","author":"S Ventz","year":"2018","unstructured":"Ventz, S., Cellamare, M., Parmigiani, G. & Trippa, L. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics 19, 199\u2013215 (2018).","journal-title":"Biostatistics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72984-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:23:36Z","timestamp":1783981416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72984-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72984"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72984-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.J.H., E.M.R., and J.D.S. have received in-kind assay support for research from Naveris and Natera. G.J.H. has served in a consulting and advisory role for Naveris, Natera, and Adela. All remaining authors have declared no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6142"}}